Zetta Genomics, a startup based in Cambridge, UK, has secured $2.36 million in seed funding from investors including Cambridge Enterprise, APEX Ventures, and Nina Capital. The company is on a mission to unlock the potential of precision medicine by leveraging genomic data to transform the health outcomes of millions of people globally.

Zetta Genomics is at the forefront of biotechnology research, developing cutting-edge technologies and solutions to harness the power of genomic data for precision medicine. The company's innovative approach involves using advanced analytics and data-driven insights to identify personalized treatment options for patients based on their genetic makeup, ultimately improving the effectiveness and safety of medical treatments.

With the seed funding, Zetta Genomics plans to further advance its research and development efforts, expand its capabilities, and accelerate its mission to revolutionize precision medicine. The company's groundbreaking work has gained recognition from investors, who see the potential of genomic data in transforming healthcare outcomes and improving patient care.

Zetta Genomics' vision for precision medicine has the potential to revolutionize the field of biotechnology and bring significant advancements in personalized healthcare. The funding secured will support the company's efforts to unlock the power of genomic data and drive positive changes in the lives of millions of people worldwide by advancing the field of precision medicine. Visit us for more information about their latest funding round: https://founderlodge.com/round/Zetta-Genomics-Ltd-raises-2357000-Seed-2023-04-21-Mark-Bailey-MTIzNTc